Mirxes

US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up

The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’

Mirxes specialises in miRNA technology, developing blood-based diagnostic tests for the early detection of cancer and other diseases.

Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments

Trading in company’s shares is suspended until its results are published

The Hong Kong-listed company did not declare any dividend for the six-month period.

A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows

Higher revenue is driven by increased contributions from its early detection and precision multi-omics segment 

Mirxes is still considering a secondary listing in Singapore, says CEO Dr Zhou Lihan.

‘A fighting chance’: Mirxes on why it chose Hong Kong over Singapore for its IPO

Chief executive Dr Zhou Lihan says Hong Kong offered a better valuation and a more savvy investor pool

Mirxes co-founder Zhou Lihan says the company hopes to tap Hong Kong and China's healthcare and biotech investor base.

Singapore biotech Mirxes files for Hong Kong IPO after raising US$50 million

CANCER diagnostics company Mirxes has applied to Hong Kong’s stock exchange for an initial public offering (IPO), potentially becoming the first company based outside of China and Hong Kong to list un...